1. Protective role of resolvin D1, a pro-resolving lipid mediator, in nonsteroidal anti-inflammatory drug-induced small intestinal damage
- Author
-
Akira Higashimori, Tetsuya Tanigawa, Koji Otani, Yasuaki Nagami, Yuji Nadatani, Shuhei Hosomi, Noriko Kamata, Fumio Tanaka, Hiroyuki Kitamura, Shusei Fukunaga, Toshio Watanabe, Takuya Kuzumoto, Yasuhiro Fujiwara, and Koichi Taira
- Subjects
Male ,0301 basic medicine ,Chemokine ,NSAIDs ,Chemokine CXCL1 ,Gene Expression ,Pharmacology ,Mice ,White Blood Cells ,chemistry.chemical_compound ,0302 clinical medicine ,Animal Cells ,Intestine, Small ,Medicine and Health Sciences ,Arachidonate 15-Lipoxygenase ,Lipoxygenase Inhibitors ,Intestinal Mucosa ,Immune Response ,Analgesics ,Multidisciplinary ,biology ,Chemistry ,Anti-Inflammatory Agents, Non-Steroidal ,Drugs ,Animal Models ,Lipids ,CXCL1 ,medicine.anatomical_structure ,Pharmaceutical Preparations ,Experimental Organism Systems ,030220 oncology & carcinogenesis ,Cytokines ,Small Intestine ,Medicine ,Tumor necrosis factor alpha ,Anatomy ,Cellular Types ,medicine.symptom ,Research Article ,Histology ,Docosahexaenoic Acids ,Drug-Related Side Effects and Adverse Reactions ,Immune Cells ,Science ,Immunology ,Mouse Models ,Inflammation ,Protective Agents ,Research and Analysis Methods ,Formyl peptide receptor 2 ,Proinflammatory cytokine ,03 medical and health sciences ,Signs and Symptoms ,Model Organisms ,Genetics ,medicine ,Animals ,Blood Cells ,Macrophages ,Biology and Life Sciences ,Cell Biology ,Pain management ,Small intestine ,Baicalein ,Mice, Inbred C57BL ,Gastrointestinal Tract ,Disease Models, Animal ,030104 developmental biology ,Animal Studies ,biology.protein ,Clinical Medicine ,Digestive System - Abstract
Resolvin D1, a specialized pro-resolving lipid mediator produced from docosahexaenoic acid by 15- and 5-lipoxygenase, exerts anti-inflammatory effects driving to the resolution of inflammation. The present study aimed to elucidate its role in small intestinal damage induced by nonsteroidal anti-inflammatory drug (NSAID). Indomethacin was administered orally to C57BL/6J male mice, which were sacrificed 24 h later to collect small intestine specimens. Before administration of indomethacin, mice were subjected to intraperitoneal treatment with resolvin D1 or oral administration of baicalein, a 15-lipoxygenase inhibitor. Small intestinal damage induced by indomethacin was attenuated by pretreatment with resolvin D1. Furthermore, resolvin D1 reduced the gene expression levels of interleukin-1β, tumor necrosis factor-α, and CXCL1/keratinocyte chemoattractant. Conversely, the inhibition of 15-lipoxygenase activity by baicalein increased the expression of genes coding for these inflammatory cytokines and chemokine, leading to exacerbated small intestinal damage, and reduced the concentration of resolvin D1 in the small intestinal tissue. Exogenous treatment with resolvin D1 negated the deleterious effect of baicalein. 15-lipoxygenase was mainly expressed in the epithelium and inflammatory cells of the small intestine, and its gene and protein expression was not affected by the administration of indomethacin. Inhibition of the resolvin D1 receptor, lipoxin A4 receptor /formyl peptide receptor 2, by its specific inhibitors Boc-1 and WRW4 aggravated indomethacin-induced small intestinal damage. Collectively, these results indicate that resolvin D1 produced by 15-lipoxygenase contributes to mucoprotection against NSAID-induced small intestinal damage through its anti-inflammatory effect.
- Published
- 2021